Literature DB >> 1689886

Early trials with FK 506 as primary treatment in liver transplantation.

S Todo1, J J Fung, A J Demetris, A Jain, R Venkataramanan, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1689886      PMCID： PMC2903882     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Liver transplantation (1).

Authors:  T E Starzl; A J Demetris; D Van Thiel
Journal:  N Engl J Med       Date:  1989-10-12       Impact factor: 91.245

Review 2.  Liver transplantation (2).

Authors:  T E Starzl; A J Demetris; D Van Thiel
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

3.  Equitable allocation of extrarenal organs: with special reference to the liver.

Authors:  T E Starzl; R D Gordon; A Tzakis; S Staschak; V Fioravanti; B Broznick; L Makowka; H T Bahnson
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

4.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321
  4 in total
  31 in total

1.  Effect of renal ischemia on plasma levels of FK 506 in rats.

Authors:  M Sakr; G Zetti; J Gavaler; H Farghali; R Venkataramanan; G Carrieri; T Starzl; D Van Thiel
Journal:  Transplant Proc       Date:  1992-02       Impact factor: 1.066

Review 2.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

3.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

4.  Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report.

Authors:  L A Mieles; J J Fung; I Yokoyama; J McCauley; N Singh; S Todo; R D Gordon; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

Authors:  J Fung; K Abu-Elmagd; A Jain; R Gordon; A Tzakis; S Todo; S Takaya; M Alessiani; A Demetris; O Bronster
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C W Jensen; V Scantlebury; J Fung; A Tzakis; J McCauley; A Jain; J Demetrius; P Randhawa
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 7.  Adverse effects associated with the use of FK 506.

Authors:  J J Fung; M Alessiani; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; D Van Thiel; J Armitage; A Jain; J McCauley
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation.

Authors:  J M Armitage; R L Kormos; J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.

Authors:  J M Armitage; R L Kormos; B P Griffith; R L Hardesty; F J Fricker; R S Stuart; G C Marrone; S Todo; J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 10.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.